UPR vs. PRTC, CRW, AMS, ONT, MXCT, BMK, NIOX, BVXP, SPI, and OXB
Should you be buying Uniphar stock or one of its competitors? The main competitors of Uniphar include PureTech Health (PRTC), Craneware (CRW), Advanced Medical Solutions Group (AMS), Oxford Nanopore Technologies (ONT), MaxCyte (MXCT), Benchmark (BMK), NIOX Group (NIOX), Bioventix (BVXP), Spire Healthcare Group (SPI), and Oxford Biomedica (OXB). These companies are all part of the "medical" sector.
PureTech Health (LON:PRTC) and Uniphar (LON:UPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
80.3% of PureTech Health shares are held by institutional investors. Comparatively, 49.3% of Uniphar shares are held by institutional investors. 14.8% of PureTech Health shares are held by company insiders. Comparatively, 10.1% of Uniphar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
PureTech Health has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Uniphar has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
In the previous week, Uniphar's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.
Uniphar has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.
Uniphar has a net margin of 1.75% compared to Uniphar's net margin of 0.00%. PureTech Health's return on equity of 14.48% beat Uniphar's return on equity.
PureTech Health received 524 more outperform votes than Uniphar when rated by MarketBeat users. However, 100.00% of users gave Uniphar an outperform vote while only 86.58% of users gave PureTech Health an outperform vote.
Summary
Uniphar beats PureTech Health on 8 of the 13 factors compared between the two stocks.
Get Uniphar News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
